Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict | Los Angeles Business Journal
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Puma Biotechnology (NASDAQ:PBYI) Upgraded to Buy by Citigroup - Opera News
Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference | Business Wire
puma biotechnology stock news Off 62% - canerofset.com
puma biotechnology stock news Off 62% - canerofset.com
puma biotechnology stock news Off 62% - canerofset.com
Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meeting | Business Wire
Why Puma Biotechnology, Inc. Stock Soared 65.1% in July | Nasdaq
Puma Biotechnology Releases Updated Corporate Presentation | Business Wire
Puma Biotechnology Crashed After Lagging More Bullish Views For Breast Cancer Drug Nerlynx | Stock News & Stock Market Analysis - IBD
Puma Biotechnology
Puma Biotechnology shares rocket after biopharma zips past Street's 4Q estimate
In the wake of Puma Biotechnology, Inc.'s (NASDAQ:PBYI) latest US$17m market cap drop, institutional owners may be forced to take severe actions - Simply Wall St News
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meeting | Business Wire
Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020 | Business Wire
Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data (NASDAQ:PBYI) | Seeking Alpha
puma biotechnology stock news Off 62% - canerofset.com
Why Puma Biotechnology Is Soaring Today | The Motley Fool
Puma Biotech's Nerlynx Wins Canadian Approval In HER2-Positive Metastatic Breast Cancer | Markets Insider
Puma Biotechnology says its breast cancer therapy included in two key NCCN updates | Seeking Alpha
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS
